Search results
Added:
11 months ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyIn the landmark FAIR-HF2 randomized clinical trial (NCT03036462)1, intravenous (IV) ferric carboxymaltose did not significantly reduce heart failure (HF) hospitalizations or cardiovascular deaths in patients with heart failure and iron deficiency, despite improving patient-reported quality of life outcomes. Results were presented at ACC.252 and concurrently published in JAMA3…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
Added:
11 months ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyA significant improvement in the use of guideline-directed quadruple medical therapy (QMT) for heart failure with reduced ejection fraction (HFrEF) has been achieved through the IMPLEMENT-HF initiative, according to results published in Circulation: Heart Failure1. Over two years, participating hospitals increased the rate of defect-free QMT at discharge dramatically—from just…
View more
Added:
1 week ago
Source:
CFR Journal
Consumer wearable devices may offer a scalable method for the daily monitoring of heart failure (HF) symptoms and predicting exacerbations. A new study has detailed how a deep learning model using Apple Watch data can estimate cardiopulmonary fitness and provide early risk discrimination for unplanned healthcare events in patients with HF.¹MethodologyThe Ted Rogers Understanding Exacerbations of…
View more
Added:
1 month ago
Source:
Arrhythmia Academy
Artificial intelligence applied to electrocardiograms (ECG-AI) may offer a scalable way to identify individuals at high risk of developing heart failure (HF), potentially improving on current clinical risk estimators, according to a new pooled cohort analysis from the HeartShare/Accelerating Medicines Partnership (AMP) Heart Failure program.¹The study aimed to assess whether ECG-AI models…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
Added:
1 year ago
Source:
Heart Failure 2024
Heart Failure Congress 2024 has unveiled 8 Late-breaking trial sessions for 2024.Heart Failure 2024 will take place at the Lisbon Congress Center in May. Access the full Programme here.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators, and keep up to date with our Late-Breaker Discussions with Dr Van Spall.Late…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
A new nationwide cohort study from France suggests that a simple risk stratification tool based on administrative data could help tailor cardiologist follow-up for patients with heart failure (HF), potentially improving survival and optimising resource use. The study found that 40% of patients with HF do not have an annual cardiology consultation, regardless of their disease severity.¹The French…
View more